Hydroxylansoprazole methods

Abstract

Methods and compositions are disclosed utilizing hydroxylansoprazole for the treatment of ulcers in humans. Hydroxylansoprazole exhibits a lessened liability toward drug-drug interactions than lansoprazole and a more predictable dosing regimen than lansoprazole. Hydroxylansoprazole is also useful for the treatment of gastroesophageal reflux and other conditions related to gastric hypersecretion such as Zollinger-Ellison Syndrome.

What is claimed is:  
     
         1 . A method of treating a disease chosen from the group consisting of psoriasis, ulcers, gastroesophageal reflux and conditions caused by or contributed to by gastric hypersecretion, said method comprising administering to a human a therapeutically effective amount of hydroxylansoprazole or a pharmaceutically acceptable salt thereof.  
     
     
         2 . A method according to  claim 1  of treating ulcers which comprises administering to a human a therapeutically effective amount of hydroxylansoprazole or a pharmaceutically acceptable salt thereof.  
     
     
         3 . A method according to  claim 1  of treating gastroesophageal reflux disease which comprises administering to a human a therapeutically effective amount of hydroxylansoprazole or a pharmaceutically acceptable salt thereof.  
     
     
         4 . A method according to  claim 1  of treating a condition caused by or contributed to by gastric hypersecretion which comprises administering to a human a therapeutically effective amount of hydroxylansoprazole or a pharmaceutically acceptable salt thereof.  
     
     
         5 . The method according to  claim 4  wherein said condition is Zollinger-Ellison Syndrome.  
     
     
         6 . A method according to  claim 1  of treating psoriasis which comprises administering to a human a therapeutically effective amount of hydroxylansoprazole or a pharmaceutically acceptable salt thereof.  
     
     
         7 . The method of  claim 1  wherein racemic hydroxylansoprazole is administered.  
     
     
         8 . The method of  claim 7  wherein the amount of racemic hydroxylansoprazole or a pharmaceutically acceptable salt thereof administered is from about 50 mg to about 1500 mg per day.  
     
     
         9 . The method of  claim 7  wherein racemic hydroxylansoprazole is administered orally.  
     
     
         10 . The method of  claim 1  wherein optically pure (+)-hydroxylansoprazole is administered.  
     
     
         11 . The method of  claim 10  wherein the amount of (+)-hydroxylansoprazole or a pharmaceutically acceptable salt thereof administered is from about 50 mg to about 1000 mg per day.  
     
     
         12 . The method of  claim 10  wherein optically pure (+)-hydroxylansoprazole is administered orally.  
     
     
         13 . The method of  claim 1  wherein optically pure (−)-hydroxylansoprazole is administered.  
     
     
         14 . The method of  claim 13  wherein the amount of (−)-hydroxylansoprazole or a pharmaceutically acceptable salt thereof administered is from about 50 mg to about 1000 mg per day.  
     
     
         15 . The method of  claim 13  wherein optically pure (−)-hydroxylansoprazole is administered orally.